Galapagos NV (NASDAQ:GLPG) Short Interest Update

Galapagos NV (NASDAQ:GLPG - Get Free Report) saw a significant increase in short interest during the month of February. As of February 28th, there was short interest totalling 2,170,000 shares, an increase of 25.4% from the February 13th total of 1,730,000 shares. Based on an average daily trading volume, of 262,700 shares, the days-to-cover ratio is currently 8.3 days. Currently, 4.5% of the shares of the company are short sold.

Galapagos Trading Up 1.0 %

GLPG stock traded up $0.27 on Friday, reaching $25.99. 85,838 shares of the company's stock were exchanged, compared to its average volume of 184,062. The stock has a fifty day moving average of $24.90 and a 200-day moving average of $27.06. Galapagos has a twelve month low of $22.36 and a twelve month high of $33.84.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GLPG. R Squared Ltd acquired a new position in Galapagos during the fourth quarter worth $26,000. GAMMA Investing LLC grew its holdings in Galapagos by 77.4% in the fourth quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company's stock valued at $61,000 after purchasing an additional 974 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in Galapagos by 45.9% in the fourth quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company's stock valued at $247,000 after purchasing an additional 2,824 shares during the last quarter. QRG Capital Management Inc. grew its holdings in Galapagos by 21.7% in the fourth quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company's stock valued at $288,000 after purchasing an additional 1,866 shares during the last quarter. Finally, Wealthedge Investment Advisors LLC acquired a new stake in shares of Galapagos during the fourth quarter valued at $311,000. Institutional investors and hedge funds own 32.46% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Morgan Stanley cut Galapagos from an "equal weight" rating to an "underweight" rating and cut their price target for the stock from $31.00 to $22.00 in a research note on Friday, February 14th. Barclays restated an "underweight" rating on shares of Galapagos in a research note on Thursday, January 23rd. Finally, TD Cowen cut Galapagos from a "strong-buy" rating to a "strong sell" rating in a research note on Thursday, January 9th. Five analysts have rated the stock with a sell rating and four have issued a hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Reduce" and a consensus target price of $26.75.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.